Lifecore Q2 Revenue Drops 6.2% to $34.2M, Reaffirms Full-Year Guidance
LFCR sits 25% above its 52-week low of $3.625.
Summary
Lifecore Biomedical reported Q2 2026 revenue of $34.2 million, a 6.2% decline from the prior year, alongside a net loss of $6.2 million. The company reaffirmed its full-year revenue and adjusted EBITDA guidance, signaling confidence in the back half despite the top-line miss. This follows a July 2 8-K disclosing a $52.1 million preferred stock redemption demand that exceeds current liquidity, and today's 10-Q confirms a $50.2 million obligation due December 28 that requires lender consent to fund. The reaffirmed guidance provides some relief, but the liquidity overhang remains the dominant risk.
At the time of this announcement, LFCR was trading at $4.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $163.2M. The 52-week trading range was $3.63 to $8.98. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.